Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.

Esendagli D, Sarı N, Akhan S, Arslan S, Doğan Öntaş İA, Yılmaz G, Aksoy F, Kant A, Yaşar KK, Ünlü EC, Akıllı IK, Çelen MK and 12 more

Show all authors

Mermutluoğlu Ç, Dayan S, Kara E, Durhan G, Ünal S, Demirkol B, Arafat L, Çetinkaya E, Çörtük M, Durmuş Koçak N, Parmaksız ET, İnkaya AÇ

Medical principles and practice : international journal of the Kuwait University, Health Science Centre27 Jan 2025Cited by 7 (Europe PMC)

PMID39870064PMCIDPMC11936437DOI10.1159/000543773PepBankPUB-39870064

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, inhaled aviptadil shortened the average time to discharge compared with placebo.
In plain wordsIn hospitalized adults with COVID-19, inhaled aviptadil shortened the time to discharge compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseTime from hospitalization to discharge
Study
n = 80
Comparator
Placebo
Analysis
Primary
Outcome group
Intensive care and hospital outcomes · Respiratory
Studied dose
Dose not stated · inhaledAs given in this study (human).
Measurements
Time to discharge
7.8 days
aviptadil
Time to discharge
10 days
placebo
Source sentences
Summary
The average time to discharge was 7.8 ± 4.0 days in aviptadil group and 10 ± 5.0 days in placebo (p = 0.049).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint is the time from hospitalization to discharge within 30 days of treatment.
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006401
02HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, modified Borg scales on day 3 did not differ significantly between inhaled aviptadil and placebo.
In plain wordsIn hospitalized adults with COVID-19, Borg scale scores on day 3 were not different with inhaled aviptadil than with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeModified Borg scale on day 3
Study
n = 80
Comparator
Placebo
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Respiratory
Studied dose
Dose not stated · inhaledAs given in this study (human).
Source sentences
Summary
Modified Borg scales were not statistically different on day 3 (p = 0.090)
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006402
03HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, modified Borg scales on day 7 were significantly lower with inhaled aviptadil than with placebo.
In plain wordsIn hospitalized adults with COVID-19, Borg scale scores on day 7 were lower with inhaled aviptadil than with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseModified Borg scale on day 7
Study
n = 80
Comparator
Placebo
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Respiratory
Studied dose
Dose not stated · inhaledAs given in this study (human).
Source sentences
Summary
but significantly lower in the aviptadil group on day 7 (p = 0.033)
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006403
04HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, the CT lung damage score on day 1 did not differ between the inhaled aviptadil and placebo groups.
In plain wordsIn hospitalized adults with COVID-19, CT lung damage scores on day 1 were the same in both groups.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCT lung damage score on day 1
Study
n = 80
Comparator
Placebo
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Respiratory
Studied dose
Dose not stated · inhaledAs given in this study (human).
Source sentences
Summary
The CT lung damage score was not different on day 1 for both groups (p = 0.962)
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006404
05HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, improvement in the CT lung damage score on day 28 was significantly greater with inhaled aviptadil than with placebo.
In plain wordsIn hospitalized adults with COVID-19, CT lung damage improved more with inhaled aviptadil than with placebo by day 28.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseCT lung damage score improvement on day 28
Study
n = 80
Comparator
Placebo
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Respiratory
Studied dose
Dose not stated · inhaledAs given in this study (human).
Source sentences
Summary
improvement on day 28 was significantly greater in the aviptadil group (p = 0.028).
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006405
06HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19, the death rate was lower with inhaled aviptadil than with placebo; no significance test is given.
In plain wordsIn hospitalized adults with COVID-19, fewer people died with inhaled aviptadil than with placebo, but the abstract gives no significance test.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseDeath rate
Study
n = 80
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
Dose not stated · inhaledAs given in this study (human).
Measurements
Death rate
5.1%
aviptadil
Death rate
12.2%
placebo
Source sentences
Summary
The death rate was also lower in the aviptadil group (5.1%) when compared to the placebo (12.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006406
07HumanRandomized controlled trialSafety outcome
In hospitalized adults with COVID-19, no participant dropped out of the trial because of side effects of inhaled aviptadil.
In plain wordsIn hospitalized adults with COVID-19, no one left the trial because of side effects of inhaled aviptadil.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeDrop-out due to side effects
Study
n = 80
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · inhaledAs given in this study (human).
Source sentences
Summary
There was no drop-out due to side effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Summary · context
Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care.
Report a problemFND-3987006407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04844580

A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

Centurion Pharman = 8010 Mar 2021 to 22 Nov 2022

Covid19

Trial page ClinicalTrials.govUpdated 5 Jun 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:40 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.